Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication

Executive Summary

Panel’s vote to approve Sprout’s female sexual dysfunction drug is conditioned on a REMS and possible contraindication with alcohol use; questions about drug’s date rape potential, breast cancer finding in mice addressed.


Related Content

Female Libido Booster Found In Supplements: Health And Wellness Industry News
FDA Adds New Co-Primary Endpoint For Female Sexual Desire Drugs
FDA Reviewers Disagreed About Approval Of Sprout's Addyi
Valeant Still Holding Off On DTC Ads For Controversial Female Sex Pill
Women’s Intuition: What Approval Of Sprout’s Addyi Means For Sponsors
Valeant Buyout Brings Marketing Clout To Sprout And Addyi
Now Sprout Has To Sell Female Sexual Desire Drug Addyi
Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed
Flibanserin Risk Management Challenges: Can A REMS Prevent Alcohol Interactions?
Flibanserin Fails To Improve Sexual Desire, FDA Advisory Committee Says


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts